BTIG Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $43
Portfolio Pulse from Benzinga Newsdesk
BTIG has initiated coverage on Abivax (NASDAQ:ABVX) with a Buy rating and set a price target of $43.
May 20, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG has initiated coverage on Abivax with a Buy rating and set a price target of $43, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $43 by BTIG is likely to boost investor confidence and attract new investments, leading to a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100